MetaCap

Fortress Biotech (FBIO) vs PMV Pharmaceuticals (PMVP)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Fortress Biotech (FBIO) has outperformed PMV Pharmaceuticals (PMVP) over the past year, losing 26.6% versus a loss of 33.6%. Over five years, FBIO leads with a -95.5% price change compared with -96.2% for PMVP. PMV Pharmaceuticals is the larger company by market cap ($66.2 million vs $64.1 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

FBIO-26.64%PMVP-33.64%
+74%+18%-39%
Nov 21, 20251 yearNov 20, 2026
FBIO-95.90%PMVP-96.51%
+5%-49%-102%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

FBIO versus PMVP key metrics
MetricFBIOPMVP
Share price$1.90$0.876
Market cap$64.11M$66.17M
1-day change+7.34%-33.13%
YTD return-48.09%-29.92%
1-year return-26.64%-33.64%
5-year return-95.52%-96.22%
P/E ratio (TTM)0.83—
EPS (TTM)$2.30$-1.56
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$63.26M—
Revenue growth (YoY)+9.69%—
Net income (latest FY)$6.82M$-77.74M
Gross margin66.92%—
Operating margin-111.00%—
Net margin10.77%—
52-week high$4.53$1.91
52-week low$1.64$0.66
Distance from 52-week high-58.06%-54.14%
Analyst consensusnonestrong_buy
Avg. price target upside+163.16%+356.62%
Average volume281.49K787.50K
Shares outstanding33.74M75.53M
Employees7854
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Fortress Biotech

FBIO stock →

Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 78 employees

About PMV Pharmaceuticals

PMVP stock →

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 54 employees

FBIO vs PMVP FAQ

Which is bigger, Fortress Biotech or PMV Pharmaceuticals?

PMV Pharmaceuticals (PMVP) is larger, with a market capitalization of $66.17M compared with $64.11M for Fortress Biotech (FBIO).

Which stock has performed better over the past year, FBIO or PMVP?

FBIO returned -26.64% over the past 12 months, compared with -33.64% for PMVP (price return, excluding dividends). Past performance does not predict future results.

Are Fortress Biotech and PMV Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons